ArticleEnvironmental research2026
Association between gestational PFAS exposure biomarkers and risk of preeclampsia in the ECHO Cohort.
Article in Environmental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stress-activated pathways mediate PFAS effects on human placental syncytiotrophoblast cells.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Preeclampsia represents a major public health problem and contributes to maternal and child morbidity and mortality. Environmental exposure to per- and polyfluoroalkyl substances (PFAS) may increase the risk of preeclampsia. We investigated associations between 6 gestational PFAS exposure biomarkers and odds of preeclampsia among 2,343 women in the Environmental influences on Child Health Outcomes (ECHO) Cohort. We evaluated effect modification by race and fetal sex, and mixture effects with quantile g-computation and BKMR. Odds ratios (ORs) were elevated for perfluorooctanoic acid (PFOA; OR: 1.27 [0.73-2.23]), perfluorononanoic acid (PFNA; OR: 1.13 [0.85-1.49]), and perfluorodecanoic acid (PFDA; OR: 1.24 [0.92-1.65]) but reduced for perfluorohexane-1-sulfonic acid (PFHXS; OR: 0.78 [0.57-1.06]) and N-methyl perfluorooctane sulfonamido acetic acid (FOSAA; OR: 0.65 [0.24-1.76]). An interquartile range increase in PFDA was associated with 1.40 (95 % CI: 0.95-2.05) times greater odds of preeclampsia among pregnancies carrying female fetuses (OR: 1.09, 95 % CI: 0.73-1.62) and 2.28 (95 % CI: 1.26-4.12) times greater odds among those of Hispanic ethnicity compared with non-Hispanic White (OR: 0.96, 95 % CI: 0.62-1.48). Mixture analyses detected interactions between several PFAS chemicals. Our findings indicate suggestive trends of elevated susceptibility to preeclampsia with increasing PFAS exposure among pregnancies with a female fetus and races and ethnicities other than non-Hispanic White.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.